FourKites Launches New Tools and Powerful Enhancements to Increase the Adoption of Supply Chain Visibility and Accelerate Time to Value
1.9.2021 11:00:00 EEST | Business Wire | Press release
FourKites ®, the world’s leading real-time supply chain visibility platform, has released powerful new capabilities designed to help shippers, carriers and forwarders more quickly and easily collaborate to increase end customer satisfaction, reduce supply chain costs and increase on-time delivery performance. With ever-increasing demand, supply chain visibility has become table stakes for modern supply chains, and seamless connection and communication between carriers and shippers has never been more important. FourKites’ combination of swift carrier connections, powerful collaboration tools and the industry’s highest-quality real-time logistics data provides shippers and their forwarder/carrier partners with robust assurances of rapid, frictionless implementation and faster time to value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005371/en/
FourKites Launches New Tools and Powerful Enhancements to Increase the Adoption of Supply Chain Visibility and Accelerate Time to Value (Photo: Business Wire)
- Instant Messenger, now with extended capabilities that allow shippers to chat directly with forwarders and carriers, gives supply chain partners the ability to view and share important information and resolve issues together, in real time. Without leaving the FourKites platform, track-and-trace and dispatch workers, drivers and warehouse personnel can view the critical information that affects shipments and deliveries — all in one single interface. Users can share documents, photographs and notes for any given load, as well as form online workgroups and control access as needed.
- CarrierLink ®, the industry’s most downloaded visibility app for drivers, now includes improved turn-by-turn navigation for better route optimisation; mobile check-in; and new capabilities for updating appointment times, adding notes to loads and uploading paperwork. It also features enhanced capabilities for viewing fuel stops, weigh stations, location ratings and amenities along routes.
"We have hundreds of carriers within our network, from the courier side to the truckload side. When it comes to onboarding, FourKites has been fantastic,” said Josh Dolan, VP of Global Logistics, Cardinal Health. “They've done a phenomenal job working with carriers through the process and helping us fill the gap with new technologies that simplify and speed up onboarding, and enhance communication between Cardinal Health and our partners."
The German multinational Bayer saves time while increasing customer satisfaction thanks to FourKites’ supply chain visibility platform. The impact has already been so strong that the company has made visibility an essential part of its long term strategy.
“Every day, our carriers automatically share location data with our FourKites platform on hundreds of loads throughout Europe,” says Edmund Jager, Head of Distribution EMEA at Bayer. “We are able to track our products minute by minute and, in real time, pass on detailed arrival times to our customers. This means the distributors we supply always know their stock situation and end customers can depend on us to get them the seeds and crop protection they need, when they need them. We look forward to onboarding more carriers and so strengthen our customer-centric approach.”
In addition, FourKites recently announced its industry-first Tracking Quality Guarantee, which establishes the highest standards in supply chain data, guaranteeing real-time visibility and predictive intelligence into a minimum of 90% of customers’ shipments — end-to-end and across every mode and geography. This differentiated approach gives supply chain partners the collaborative opportunities and network effects they need to improve customer satisfaction and optimise their supply chain performance.
“As the first mover and leading innovator in real-time visibility and supply chain management solutions, FourKites is committed to helping shippers, forwarders and carriers achieve end-to-end supply chain visibility faster, and with assurances of the highest-quality tracking in the industry,” said FourKites founder and CEO Mathew Elenjickal. “We are excited to make these powerful new capabilities available to the community to enable greater collaboration and communication, and ultimately, value.”
About FourKites
FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 600 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005371/en/
Contact information
Scott Johnston
European PR Lead for FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release
Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
